These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24047449)

  • 21. Prevalence and Predictors of White Coat Hypertension among Newly-Diagnosed Hypertensive Patients in a Tertiary Health Centre in Nigeria.
    Dele-Ojo B; Kolo P; Ogunmodede A; Bello H; Katibi I; Omotoso A; Dada S
    Ethiop J Health Sci; 2019 Jul; 29(4):431-438. PubMed ID: 31447515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cutoffs for white-coat and masked blood pressure effects: an ambulatory blood pressure monitoring study.
    Dal Pont CS; Feitosa ADM; Bezerra R; Martins AHB; Viana GM; Starke S; Azevedo GSA; Mota-Gomes MA; Barroso WS; Miranda RD; Barbosa ECD; Brandão AA; Feitosa CLDM; Gonçalves TAT; Nobre F; Mion D; Sposito AC; Nadruz W
    J Hum Hypertens; 2024 Aug; 38(8):595-602. PubMed ID: 38987381
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Central pressures and central hemodynamic values in white coat hypertensives are closer to those of normotensives than to those of controlled hypertensives for similar age, gender, and 24-h and nocturnal blood pressures.
    Almeida J; Monteiro J; Silva JA; Bertoquini S; Polónia J
    Rev Port Cardiol; 2016 Nov; 35(11):559-567. PubMed ID: 27717519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treated hypertension and the white coat phenomenon: Office readings are inadequate measures of efficacy.
    Agarwal R; Weir MR
    J Am Soc Hypertens; 2013; 7(3):236-43. PubMed ID: 23523137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toward a definition of masked hypertension and white-coat hypertension among hemodialysis patients.
    Agarwal R; Sinha AD; Light RP
    Clin J Am Soc Nephrol; 2011 Aug; 6(8):2003-8. PubMed ID: 21737856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of white-coat hypertension on microvascular complications in type 2 diabetes.
    Kramer CK; Leitão CB; Canani LH; Gross JL
    Diabetes Care; 2008 Dec; 31(12):2233-7. PubMed ID: 18768675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Task force IV: Clinical use of ambulatory blood pressure monitoring. Participants of the 1999 Consensus Conference on Ambulatory Blood Pressure Monitoring.
    Staessen JA; Beilin L; Parati G; Waeber B; White W
    Blood Press Monit; 1999 Dec; 4(6):319-31. PubMed ID: 10602536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. White-Coat and Reverse White-Coat Effects Correlate with 24-h Pulse Pressure and Systolic Blood Pressure Variability in Children and Young Adults.
    Fujita H; Matsuoka S; Awazu M
    Pediatr Cardiol; 2016 Feb; 37(2):345-52. PubMed ID: 26481222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. White coat effect and white coat hypertension in pediatric patients.
    Matsuoka S; Kawamura K; Honda M; Awazu M
    Pediatr Nephrol; 2002 Nov; 17(11):950-3. PubMed ID: 12432440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discordance between ambulatory versus clinic blood pressure according to global cardiovascular risk group.
    Shin J; Park SH; Kim JH; Ihm SH; Kim KI; Kim WS; Pyun WB; Kim YM; Choi SI; Kim SK
    Korean J Intern Med; 2015 Sep; 30(5):610-9. PubMed ID: 26354055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnosis of white coat hypertension by ambulatory blood pressure monitoring.
    Owens P; Atkins N; O'Brien E
    Hypertension; 1999 Aug; 34(2):267-72. PubMed ID: 10454452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic criteria of white coat hypertension (WCH): consequences for the implications of WCH for target organs.
    Pose-Reino A; Rodríguez-Fernández M; López-Barreiro L; Coleman IC; Estévez-Nuñez JC; Méndez-Naya I
    Blood Press; 2002; 11(3):144-50. PubMed ID: 12126260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse prognostic value of persistent office blood pressure elevation in white coat hypertension.
    Mancia G; Facchetti R; Grassi G; Bombelli M
    Hypertension; 2015 Aug; 66(2):437-44. PubMed ID: 26056342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Target Organ Complications and Cardiovascular Events Associated With Masked Hypertension and White-Coat Hypertension: Analysis From the Dallas Heart Study.
    Tientcheu D; Ayers C; Das SR; McGuire DK; de Lemos JA; Khera A; Kaplan N; Victor R; Vongpatanasin W
    J Am Coll Cardiol; 2015 Nov; 66(20):2159-2169. PubMed ID: 26564592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. White-coat hypertension/effect is associated with higher arterial stiffness and stroke events.
    Saunders A; Nuredini GN; Kirkham FA; Drazich E; Bunting E; Rankin P; Ali K; Okorie M; Rajkumar C
    J Hypertens; 2022 Apr; 40(4):758-764. PubMed ID: 35001033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Possible cardiovascular risks of white coat hypertension: updated.
    Chrysant SG
    Postgrad Med; 2023 Jun; 135(5):466-471. PubMed ID: 37161879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of preeclampsia in pregnant women with white-coat hypertension: a systematic review and meta-analysis.
    Hadizadeh S; Shahmohamadi E; Khezerlouy-Aghdam N; Heidary L; Tarafdari A; Hantoushzadeh S; Ayati A; Foroutani L; Ahmadi-Tafti H; Mohseni-Badalabadi R; Vahidi H; Hadizadeh A; Mousavi S
    Arch Gynecol Obstet; 2024 Mar; 309(3):929-937. PubMed ID: 37792010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. White coat effect and masked uncontrolled hypertension in treated hypertensive-diabetic patients: Prevalence and target organ damage.
    Leiria LF; Severo MD; Ledur PS; Becker AD; Aguiar FM; Massierer D; Freitas VC; Schaan BD; Gus M
    J Diabetes; 2015 Sep; 7(5):699-707. PubMed ID: 25327439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Cardiovascular Risk of White-Coat Hypertension.
    Franklin SS; Thijs L; Asayama K; Li Y; Hansen TW; Boggia J; Jacobs L; Zhang Z; Kikuya M; Björklund-Bodegård K; Ohkubo T; Yang WY; Jeppesen J; Dolan E; Kuznetsova T; Stolarz-Skrzypek K; Tikhonoff V; Malyutina S; Casiglia E; Nikitin Y; Lind L; Sandoya E; Kawecka-Jaszcz K; Filipovský J; Imai Y; Wang JG; O'Brien E; Staessen JA;
    J Am Coll Cardiol; 2016 Nov; 68(19):2033-2043. PubMed ID: 27810041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. C-reactive protein and nitric oxide level in patients with white coat hypertension.
    Guven A; Tolun F; Caliskan M; Ciftci O; Muderrisoglu H
    Blood Press; 2012 Oct; 21(5):281-5. PubMed ID: 22229480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.